Staar Surgical (STAA) FY2025 results: revenue $239 million, down 23.7% on the year
Staar Surgical Co. (STAA) reported revenue of $239 million for fiscal 2025, the year ended 2 January 2026, down 23.7% on the year before. Net income was -$80 million, and diluted earnings per share $-1.62. The figures are the company's own, from the 10-K it filed with the SEC on 3 March 2026.
Revenue
$239 million
-23.7% on the year
FY2018FY2025
Operating margin
-38.3%
-4.0% a year earlier
FY2018FY2025
Net income
-$80 million
FY2018FY2025
Diluted EPS
-$1.62
FY2018FY2025
this yearthe year beforeHover a bar for its figure.
The year in brief
What management said about the year
Fourth-quarter sales rose 18.1%: Net sales were $57.8 million, up 18.1%. The company attributed the increase primarily to sales growth in China.
Full-year sales fell on China: Fiscal 2025 net sales were $239.4 million, down 23.7% from $313.9 million, as China distributor and channel inventory was reduced in the first half.
Fourth-quarter China sales held back: Management said in-market recovery in China did not lift STAAR sales in the fourth quarter because sub-distributor and customer inventory was reduced.
EVO+ early China demand exceeded expectations: Initial EVO+ shipments from Switzerland to China began in November 2025, and management said early customer demand has exceeded expectations.
Fourth-quarter operating costs fell 8.2%: Fourth-quarter operating expenses excluding merger and restructuring costs were $54.7 million, down 8.2%. Lower advertising and promotional spending was cited.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2025
FY2024
FY2023
On the year
Last 8 years
Operating cash flow
-34.2
15.7
14.6
Capital expenditure
5.8
23.4
18.2
-75.1%
Free cash flow
-40.0
-7.7
-3.6
Free cash flow margin
-16.7%
-2.4%
-1.1%
Cash from investing
46.3
-59.2
74.3
Cash from financing
-4.6
5.7
7.4
Depreciation and amortisation
n/a
n/a
5.1
Share-based compensation
30.6
27.2
23.5
+12.4%
Buybacks
6.5
n/a
n/a
Diluted shares, weighted
50m
49m
49m
+0.9%
Shares outstanding at period end
49m
49m
49m
+0.2%
Balance sheet
$ million
FY2025
FY2024
FY2023
On the year
Last 8 years
Shareholders' equity
344
397
386
-13.4%
Debt
0.0
n/a
0.0
Operating lease liabilities
32.5
34.8
31.4
-6.7%
Finance lease liabilities
n/a
n/a
0.0
Other liabilities
75.0
77.4
71.3
-3.1%
Total liabilities and equity
452
510
489
-11.4%
Fixed assets
73.3
84.9
66.8
-13.6%
Goodwill
1.8
1.8
1.8
0.0%
Investments
34.4
86.3
49.4
-60.2%
Cash and equivalents
153
144
183
+6.2%
Receivables
50.1
77.9
94.7
-35.7%
Other assets
139
114
92.9
+21.4%
Total assets
452
510
489
-11.4%
10-K for the year ended 2 January 2026, filed 3 March 2026: the filing.